Back to School: How biopharma can reboot drug development. Access exclusive analysis here

FV-100: Phase I data

In a double-blind, placebo-controlled, U.S. Phase I trial (INH-FVI-001) in

Read the full 106 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE